PMID: 25742786Mar 7, 2015Paper

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification

Oncotarget
Matteo DugoMarialuisa Sensi

Abstract

Dysregulation of receptor tyrosine kinases (RTKs) contributes to several aspects of oncogenesis including drug resistance. In melanoma, distinct RTKs have been involved in BRAF inhibitors (BRAFi) resistance, yet the utility of RTKs expression pattern to identify intrinsically resistant tumors has not been assessed. Transcriptional profiling of RTKs and integration with a previous classification, reveals three robust subtypes in two independent datasets of melanoma cell lines and one cohort of melanoma samples. This classification was validated by Western blot in a panel of patient-derived melanoma cell lines. One of the subtypes identified here for the first time displayed the highest and lowest expression of EGFR and ERBB3, respectively, and included BRAF-mutant tumors all intrinsically resistant to BRAFi PLX4720, as assessed by analysis of the Cancer Cell Line Encyclopedia pharmacogenomic study and by in vitro growth inhibition assays. High levels of EGFR were detected, even before therapy, in tumor cells of one of three melanoma patients unresponsive to BRAFi. Use of different pharmacological inhibitors highlighted the relevance of PI3K/mTOR signaling for growth of this PLX4720-resistant subtype. Our results identify a speci...Continue Reading

References

Dec 26, 2001·Nucleic Acids Research·Ron EdgarAlex E Lash
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Oct 6, 2004·Genome Biology·Robert C GentlemanJianhua Zhang
Sep 22, 2005·Bioinformatics·Alan R Dabney
Apr 25, 2006·Biostatistics·W Evan JohnsonAriel Rabinovic
Apr 28, 2006·Nature Genetics·Michael ReichJill P Mesirov
May 23, 2007·Pigment Cell Research·Peter JohanssonNicholas Hayward
Jan 10, 2008·Nature Biotechnology·Mazen W KaramanPatrick P Zarrinkar
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·James TsaiGideon Bollag
May 10, 2008·Bioinformatics·Pan DuSimon M Lin
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christina K AugustineDouglas S Tyler
Nov 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Dusan BogunovicNina Bhardwaj
Dec 31, 2009·PloS One·Aaron R JeffsMichael R Eccles
Jan 26, 2010·Biostatistics·Matthew N McCallRafael A Irizarry
May 13, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Göran JönssonPer Eystein Lønning
Jun 4, 2010·PloS One·Omar KabbarahLynda Chin
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Dec 24, 2010·Pigment Cell & Melanoma Research·Marie C ZipserKeith S Hoek
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jul 29, 2011·The Journal of Investigative Dermatology·Marialuisa SensiAndrea Anichini
Jan 14, 2012·Neoplasia : an International Journal for Oncology Research·Elisabetta VerganiMonica Rodolfo
Feb 18, 2012·Pigment Cell & Melanoma Research·Daniel S WidmerKeith S Hoek
Apr 28, 2012·BMC Genomics·Tara L SpiveyFrancesco M Marincola
Jan 8, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ryan J Sullivan, Keith T Flaherty
Apr 2, 2013·The Journal of Clinical Investigation·Ethan V AbelAndrew E Aplin
May 2, 2013·The Journal of Investigative Dermatology·Leon RaskinStephen B Gruber
May 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fernando Ulloa-MontoyaVincent G Brichard
Nov 10, 2013·Nature Medicine·Piro LitoDavid B Solit
Apr 29, 2014·Cancer Discovery·David J KonieczkowskiLevi A Garraway
May 16, 2014·Pigment Cell & Melanoma Research·Curtis H Kugel, Andrew E Aplin

❮ Previous
Next ❯

Citations

Mar 3, 2017·Current Oncology Reports·Marie Schoumacher, Mike Burbridge
Jul 17, 2019·Pigment Cell & Melanoma Research·Ines Böhme, Anja Bosserhoff
Oct 9, 2019·Pigment Cell & Melanoma Research·Pakavarin LouphrasitthipholColin R Goding
Oct 3, 2019·Genes & Development·Florian RambowColin R Goding
Sep 25, 2020·Cell Communication and Signaling : CCS·Elisabetta VerganiViviana Vallacchi
Jan 5, 2017·Molecular Carcinogenesis·Mahamat BabaganaEugene S Kandel
Aug 29, 2018·Proceedings of the National Academy of Sciences of the United States of America·Kao Chin NgeowColin R Goding
Jun 18, 2019·Pigment Cell & Melanoma Research·Pakavarin LouphrasitthipholColin R Goding
Apr 2, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Wei PanXiubao Ren
Dec 7, 2017·International Journal of Cancer. Journal International Du Cancer·Stuart J GallagherPeter Hersey
Mar 10, 2020·Journal of Oncology·Sierra A Colavito
Nov 24, 2016·Oncotarget·Marialuisa SensiAntonella Tomassetti
May 24, 2019·Frontiers in Molecular Neuroscience·Lionel Larribère, Jochen Utikal
Jun 13, 2020·Molecular Cell·Pakavarin LouphrasitthipholColin R Goding
Nov 13, 2020·The American Journal of Pathology·Ashapurna SarmaMalathy P V Shekhar

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.